Clinical Guidelines
Feature

Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia

  • By

  • July 22, 2019

  • 13 min

Share

  • 1

    Acute myeloid leukemia (AML) originates from abnormal hematopoietic cells.

  • 2

    Patient age impacts response to standard induction therapy.

  • 3

    Ivosidenib is an IDH1 inhibitor for R/R AML.

  • 4

    Differentiation syndrome is a notable side effect.

  • 5

    Treatment may include stem cell transplant for eligible patients.

  • 6

    Monitoring and counseling are essential for managing adverse effects.

  • 7

    Clinical trials continue to explore combinations to improve outcomes.

Original Source(s)

Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia

  • July 22, 2019

  • 13 min

Related Content

Smarter Digital Morphology Triage

A diffusion-based approach aims to handle domain shifts, slide variability, and rare cell appearances

  • January 30, 2026

  • 3 min
When Halting Myelofibrosis Progression Fails, Try Changing Its Course Instead

The decades-long research efforts of a consortium, led by Mount Sinai researchers, to deplete myelofibrosis stem cells altogether—instead of merely stopping proliferation—has received renewed funding.

  • by

  • January 11, 2024

  • 1 min
Towards Rapid Microbial Testing Methods

We need more rapid sterility testing methods for frozen CAR-T drug products; here’s one potential approach